Conditions: Tumors
Keywords: Solid tumors (including relapsed disease) that are refractory to standard therapies or for which no effective standard therapy exists
Allocation: NON_RANDOMIZED | Intervention model: PARALLEL
Enrollment: 16
Healthy volunteers: no

Brief summary:
The primary objective of this study is to determine the maximum tolerated dose (MTD) or the maximum administered dose (MAD) of Dasatinib (BMS-354825) in patients in Japan.

Detailed description:

Arms:
arm 1: None arm 2: None arm 3: None

Interventions: intervention 1: Dasatinib intervention 2: Dasatinib intervention 3: Dasatinib
Intervention descriptions: intervention 1: tablets, Oral, 100 mg, once daily for 4 weeks intervention 2: tablets, Oral, 150 mg, once daily, 4 weeks intervention 3: tablets, Oral, 200 mg, once daily for 4 weeks

Protocol document: